Top

Published in:

Open Access 01-12-2018 | Research article

Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel

Authors: Koichi Uemura, Yasuhide Miyoshi, Takashi Kawahara, Jikuya Ryosuke, Daisuke Yamashita, Shuko Yoneyama, Yumiko Yokomizo, Kazuki Kobayashi, Takeshi Kishida, Masahiro Yao, Hiroji Uemura

Published in: BMC Cancer | Issue 1/2018

Abstract

Background

A computer-assisted diagnostic system for analyzing bone scans (BONENAVI) calculates the automated bone scan index (aBSI). Here we evaluated the aBSI as a prognostic imaging biomarker for men with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel.

Methods

We retrospectively analyzed 48 patients who received cabazitaxel for mCRPC and evaluated the ability of the aBSI to predict overall survival (OS). The Cox proportional hazards model was used to investigate the associations between baseline aBSI at cabazitaxel treatment and OS with the clinical variables as follows: age, number of cycles of docetaxel, serum prostate-specific antigen, hemoglobin (Hb), lactate dehydrogenase (LDH), and alkaline phosphatase. We determined the C-index to evaluate the discriminatory ability of our models when we included or excluded the aBSI from the analyses.

Results

The median OS after cabazitaxel treatment was 10.0 months, and patients with aBSI ≤1% achieved significantly longer OS compared with patients with aBSI ≥1%. Multivariate analysis showed that age, Hb, LDH, and aBSI were independent prognostic factors of OS. Adding aBSI to the base model increased the C-index from 0.78 to 0.80.

Conclusions

The aBSI may serve as a useful imaging biomarker for predicting OS among men with mCRPC treated with cabazitaxel. Prospective studies are required to establish the value of aBSI as prognostic imaging biomarker.

Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol. 1997;15(1):382–8.CrossRefPubMed

Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol. 1998;160(4):1220–9.CrossRefPubMed

Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J. New agents for prostate cancer. Ann Oncol. 2014;25(9):1700–9.CrossRefPubMed

Sartor O, de Bono JS. Metastatic prostate Cancer. N Engl J Med. 2018;378(7):645–57.CrossRefPubMed

de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet (London, England). 2010;376(9747):1147–54.CrossRef

Horikoshi H, Kikuchi A, Onoguchi M, Sjostrand K, Edenbrandt L. Computer-aided diagnosis system for bone scintigrams from Japanese patients: importance of training database. Ann Nucl Med. 2012;26(8):622–6.CrossRefPubMedPubMedCentral

Miyoshi Y, Uemura K, Kawahara T, Yoneyama S, Hattori Y, Teranishi JI, Ohta JI, Takebayashi S, Yokomizo Y, Hayashi N, et al. Prognostic value of automated bone scan index in men with metastatic castration-resistant prostate Cancer treated with Enzalutamide or Abiraterone acetate. Clin Genitourin Cancer. 2017;15(4):472–8.CrossRefPubMed

Reza M, Ohlsson M, Kaboteh R, Anand A, Franck-Lissbrant I, Damber JE, Widmark A, Thellenberg-Karlsson C, Budaus L, Steuber T, et al. Bone scan index as an imaging biomarker in metastatic castration-resistant prostate Cancer: a multicentre study based on patients treated with Abiraterone acetate (Zytiga) in clinical practice. Eur Urol Focus. 2016;2(5):540–6.CrossRefPubMed

Mitsui Y, Shiina H, Yamamoto Y, Haramoto M, Arichi N, Yasumoto H, Kitagaki H, Igawa M. Prediction of survival benefit using an automated bone scan index in patients with castration-resistant prostate cancer. BJU Int. 2012;110(11 Pt B):E628–34.CrossRefPubMed

10.

Uemura K, Miyoshi Y, Kawahara T, Yoneyama S, Hattori Y, Teranishi J, Kondo K, Moriyama M, Takebayashi S, Yokomizo Y, et al. Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer. BMC Cancer. 2016;16:109.CrossRefPubMedPubMedCentral

11.

Kaboteh R, Gjertsson P, Leek H, Lomsky M, Ohlsson M, Sjostrand K, Edenbrandt L. Progression of bone metastases in patients with prostate cancer - automated detection of new lesions and calculation of bone scan index. EJNMMI Res. 2013;3(1):64.CrossRefPubMedPubMedCentral

12.

Fosbol MO, Petersen PM, Daugaard G, Holm S, Kjaer A, Mortensen J. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients. Ann Nucl Med. 2018;32(1):16–21.CrossRefPubMed

13.

Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, Committee IG. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228–42.CrossRefPubMed

14.

Koizumi M, Wagatsuma K, Miyaji N, Murata T, Miwa K, Takiguchi T, Makino T, Koyama M. Evaluation of a computer-assisted diagnosis system, BONENAVI version 2, for bone scintigraphy in cancer patients in a routine clinical setting. Ann Nucl Med. 2015;29(2):138–48.CrossRefPubMed

15.

Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson PA, Bjork T, Gerdtsson A, Bjartell A, et al. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the bone scan index. Eur Urol. 2012;62(1):78–84.CrossRefPubMedPubMedCentral

16.

Armstrong AJ, Kaboteh R, Carducci MA, Damber JE, Stadler WM, Hansen M, Edenbrandt L, Forsberg G, Nordle O, Pili R, et al. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC). Urol Oncol. 2014;32(8):1308–16.CrossRefPubMed

17.

Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, Heller G, Scher HI, Larson SM, Morris MJ. Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer. J Clin Oncol. 2012;30(5):519–24.CrossRefPubMedPubMedCentral

18.

Kaboteh R, Damber JE, Gjertsson P, Hoglund P, Lomsky M, Ohlsson M, Edenbrandt L. Bone scan index: a prognostic imaging biomarker for high-risk prostate cancer patients receiving primary hormonal therapy. EJNMMI Res. 2013;3(1):9.CrossRefPubMedPubMedCentral

19.

Kalderstam J, Sadik M, Edenbrandt L, Ohlsson M. Analysis of regional bone scan index measurements for the survival of patients with prostate cancer. BMC Med Imaging. 2014;14:24.CrossRefPubMedPubMedCentral

20.

Poulsen MH, Rasmussen J, Edenbrandt L, Hoilund-Carlsen PF, Gerke O, Johansen A, Lund L. Bone scan index predicts outcome in patients with metastatic hormone sensitive prostate cancer. BJU Int. 2015;

Title: Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxel
Authors: Koichi Uemura
Yasuhide Miyoshi
Takashi Kawahara
Jikuya Ryosuke
Daisuke Yamashita
Shuko Yoneyama
Yumiko Yokomizo
Kazuki Kobayashi
Takeshi Kishida
Masahiro Yao
Hiroji Uemura
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-018-4401-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients

Quantitative nuclear histomorphometry predicts oncotype DX risk categories for early stage ER+ breast cancer

Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial

Tracing the path of cancer initiation: the AA protein-based model for cancer genesis

Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

SKA1 overexpression is associated with poor prognosis in hepatocellular carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer